New drug combo targets Hard-to-Treat breast cancer
NCT ID NCT07487519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a new drug called HLX43, which is designed to seek out and destroy cancer cells in people with advanced triple-negative breast cancer (TNBC). The study will test HLX43 alone or combined with other immune-boosting drugs. About 180 adults with TNBC that has spread or come back will take part. The goal is to see if the drug shrinks tumors and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HLX43 (an antibody-drug conjugate that targets PD-L1 and delivers a chemotherapy-like toxin to cancer cells)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced triple-negative breast cancer, potentially shrinking tumors or slowing disease progression.
- What could go wrong
- This is an early Phase 2 study with a small number of participants. The drug may not work as hoped, and side effects could include immune-related reactions or toxicity from the chemotherapy component.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, 150081, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.